Search
Mizolastine
go.drugbank.com/drugs/DB12523ApprovedMizolastine is under investigation in clinical trial NCT01928316 (A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers).
Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 CYP2D6 InhibitorsProducts: MIZOLEN 10 MG TABLETAS DE LIBERACION PROLONGADARacecadotril
go.drugbank.com/drugs/DB11696InvestigationalRacecadotril has been investigated for the basic science and treatment of Diarrhea, Acute Diarrhea, and Acute Gastroenteritis.
Categories: N-substituted GlycinesProducts: HIDRASEC® 10 MG GRANULADO PARA SUSPENSION ORAL, RAXERIN 100 MG KAPSÜL, 20 KAPSÜLSafinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalIt was approved in Europe in February 2015, and in the United States on March 21, 2017.
Categories: Cytochrome P-450 Substrates, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesProducts: Equfina Film coated Tablets 50 mg, XADAGO 50 MG TABLETAS RECUBIERTAS CON PELÍCULACholic Acid
go.drugbank.com/drugs/DB02659ApprovedInvestigationalA major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. … [PubChem] Cholic acid, formulated as Cholbam capsules, is approved by the United States Food and Drug Administration as a treatment for children and adults with bile acid synthesis disorders due to single
Categories: P-glycoprotein inducersProducts: ORPHACOL®50 MG, ORPHACOL ® 250 MGErgoloid mesylate
go.drugbank.com/drugs/DB01049Approved[A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued. … [A32912] All these components are produced by the fungus _Claviceps purpurea_ and are all derivatives of the tetracyclic compound 6-methylergonovine.
Mixtures: TOTERJİN DAMLA, 50 CCCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAcalabrutinib
go.drugbank.com/drugs/DB11703ApprovedInvestigationalAt this time, more than 35 clinical trials across 40 countries with more than 2500 patients are underway or have been completed with regards to further research into better understanding and expanding … [L10241,L42795] Also known as ACP-196, acalabrutinib is also considered a second generation BTK inhibitor because it was rationally designed to be more potent and selective than ibrutinib, theoretically
Categories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: CALQUENCE 100 MG SERT KAPSÜL, 60 ADET, CALQUENCE 100 MG SERT KAPSÜL, 56 ADETAcipimox
go.drugbank.com/drugs/DB09055ApprovedInvestigationalFlushing can be reduced by taking aspirin 20-30 min before taking Acipimox. High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout. … Acipimox is a niacin derivative used as a hypolipidemic agent.
Categories: Heterocyclic Compounds, 1-RingProducts: OLBETAM CAPSULE 250 mgBelatacept
go.drugbank.com/drugs/DB06681ApprovedInvestigationalBelatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011. … Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each.
Categories: Selective T Cell Costimulation Blocker, T Lymphocyte Costimulation Activity BlockadeProducts: NULOJIX ®250 MG/ VIAL POLVO LIOFILIZADO PARA SOLUCION INYECTABLE INTRAVENOSABrexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigationalIt also displays stronger antagonism at the 5-HT1A and 5-HT2A receptors.[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015. … It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors.
Categories: MATE 2 Inhibitors, Adrenergic alpha-1 Receptor AntagonistsProducts: REXULTI (BREXPIPRAZOLE) TABLETS 1 MG, REXULTI (BREXPIPRAZOLE) TABLETS 2 MGIndacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIt was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. … Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease.
Mixtures: ULTIBRO BREEZHALER INHALATION POWDER HARD CAPSULE 110/50 MCG, ATECTURA®BREEZHALER®150/80 MCG POLVO PARA INHALACIÓN CÁPSULA DURACategories: Adrenergic beta-2 Receptor Agonists, Heterocyclic Compounds, 2-Ring